

ATAGI recommendation for using high-dose influenza vaccine versus adjuvanted influenza vaccine in adults aged ≥ 65 years

Neither adjuvanted influenza vaccine nor high-dose influenza vaccine is recommended in preference to the other in adults aged ≥ 65 years.

Justification

The evidence suggests that high-dose influenza vaccine likely results in little to no difference in the critical outcomes of influenza-related hospitalisation and influenza-related hospital encounters (ED presentation/hospitalisation) compared with adjuvanted influenza vaccine. The adverse event profiles of the two vaccines are comparable with little or no difference in the key undesirable outcomes.

Note: NCIRS is conducting GRADE in support of ATAGI and making results available on the NCIRS website. Please read this document as a supplement to the [Australian Immunisation Handbook Influenza disease chapter](#) and the [ATAGI Annual Influenza Statement](#).